Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.
We structurally characterized the adducts of the catalytic domain of matrix metalloproteinase-3 (MMP3) with three different nonpeptidic inhibitors by solving the solution structure of one adduct [MMP3-N-isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid] and then by calculating structural models of the other two adducts using a reduced set of experimental NMR data, following a recently proposed procedure (Bertini et al. in J. Med. Chem. 48:7544-7559, 2005). The inhibitors were selected with the criteria of maintaining in all of them the same zinc-coordinating moiety and of selectively changing the substituents and/or the functional groups. The backbone dynamics on various time scales have been characterized as well. The comparison among these structures and with others previously reported allowed us to elucidate fine details of inhibitor-receptor interactions and to develop some criteria, which could guide in optimizing the design of selective inhibitors.
Alcaraz
Luis A
LA
Magnetic Resonance Center (CERM), University of Florence, Via L. Sacconi 6, Sesto Fiorentino, Italy.
Banci
Lucia
L
Bertini
Ivano
I
Cantini
Francesca
F
Donaire
Antonio
A
Gonnelli
Leonardo
L
D000595:Amino Acid Sequence; D020134:Catalytic Domain / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry; D019278:Matrix Metalloproteinase 3 / Q000737:chemistry*; D008969:Molecular Sequence Data; D011487:Protein Conformation; D012996:Solutions; D013449:Sulfonamides / Q000737:chemistry
D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; C500716:N-isobutyl-N-(4-methoxyphenylsulfonyl)glycylhydroxamic acid; D012996:Solutions; D013449:Sulfonamides; D019278:Matrix Metalloproteinase 3
J Mol Biol. 2004 Feb 20;336(3):707-16
15095982
J Med Chem. 1999 Dec 30;42(26):5426-36
10639284
Curr Med Chem. 2004 Nov;11(22):2911-77
15544483
J Magn Reson. 2003 Jan;160(1):65-73
12565051
Chem Rev. 1999 Sep 8;99(9):2735-76
11749499
Biochemistry. 1997 Apr 15;36(15):4393-8
9109646
J Mol Graph. 1990 Mar;8(1):52-6, 29
2268628
J Mol Biol. 1999 Oct 29;293(3):545-57
10543949
Methods Mol Biol. 2004;278:353-78
15318003
J Med Chem. 2005 Dec 1;48(24):7544-59
16302796
Crit Rev Oral Biol Med. 1993;4(2):197-250
8435466
Biochemistry. 1998 Oct 6;37(40):14048-56
9760240
Biochem Soc Trans. 2004 Feb;32(Pt 1):17-20
14748704
J Biol Chem. 1999 Jul 30;274(31):21491-4
10419448
Circ Res. 2003 May 2;92(8):827-39
12730128
J Am Chem Soc. 2007 Mar 7;129(9):2466-75
17269766
Protein Sci. 1995 Dec;4(12 ):2487-98
8580839
Biochemistry. 1994 Jul 12;33(27):8207-17
8031754
Curr Med Chem. 2001 Mar;8(4):425-74
11172697
J Mol Biol. 2000 Sep 22;302(3):671-89
10986126
Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13
11327577
J Am Chem Soc. 2002 Oct 30;124(43):12658-9
12392402
J Mol Biol. 2000 Aug 11;301(2):513-24
10926524
Cardiovasc Res. 2006 Feb 15;69(3):562-73
16405877
J Med Chem. 1997 Aug 1;40(16):2525-32
9258358
Curr Opin Cell Biol. 1995 Oct;7(5):728-35
8573349
Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7952-5
17096442
J Biomol NMR. 2000 Jan;16(1):23-8
10718609
Cancer Metastasis Rev. 1995 Dec;14(4):351-62
8821095
J Biomol NMR. 1996 Dec;8(4):477-86
9008363
J Med Chem. 1997 Mar 14;40(6):1026-40
9083493
J Med Chem. 1998 Sep 10;41(19):3568-71
9733482
FEBS Lett. 1991 Sep 2;289(1):4-7
1894005
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5334-9
15809432
Protein Sci. 1999 Jul;8(7):1455-62
10422833
J Med Chem. 2000 Feb 10;43(3):369-80
10669564